BEIJING, March 24 (Xinhua) -- Chinese Vice President Han Zheng met with Swire Pacific Limited chairman Merlin Swire, and Novartis CEO Vas Narasimhan on Monday in Beijing, who are here for the China ...

TOKYO (Reuters) -Swiss pharmaceutical giant Novartis says it is watching "very carefully" how the reciprocal tariff policy ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

The comprehensive restructuring of Novartis under new CEO Vas Narasimhan resulted in $15 billion in bolt-on acquisitions last year, and he wants to keep up that momentum. Speaking on Novartis ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

Chief Executive Vas Narasimhan said in an interview with The Wall Street Journal. “The bar is very high, we need to find something that’s truly differentiated, that brings something new ...

Swiss pharmaceutical giant Novartis (SIX:NOVN) is keeping a close eye on the U.S. tariff policy proposed by the Biden ...

New CEO Vas Narasimhan wants to cut Novartis' R&D costs by using digital tech – and with this in mind the firm has scaled up a project involving virtual clinical trials. The Swiss pharma company ...

Swiss pharmaceutical giant Novartis will watch "very carefully" how the reciprocal tariff policy proposed by the United States unfolds in early April, Chief Executive Vas Narasimhan said on Monday.

Chief Executive Vas Narasimhan said on Monday. U.S. President Donald Trump last month flagged potential import duties of about 25% on pharmaceuticals as part of measures affecting a range of ...